Compare AbbVie Inc (ABBV) vs EPR Properties (EPR) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

EPR Properties trades at $59.21, up 0.19% today, with a bullish technical signal supported by moving averages. The REIT shows strong profitability with a 39.93% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.26 versus $0.76 expected. Recent news highlights a $315 million Six Flags acquisition and inclusion on J.P. Morgan's July Focus List (247 Wallst, 2026-07-07).

Outlook remains positive with a consensus price target of $63.00, offering 6.4% upside. Key risks include reliance on experiential assets like theaters amid economic sensitivity, while the 6.2% dividend yield provides income support. Earnings on July 29, 2026, will be critical for validating growth trends.